Results 131 to 140 of about 43,518 (188)

Increased EGFR/HER2 Pathway Activation Contributes to Skin Tumorigenesis in <i>Tpl2</i>^-^/- Mice. [PDF]

Cancers (Basel)
Purkey LR, Mehedincu S, Irvine C, Akdag R, Little M, Kothmann WW, Rus K, Greenberg E, Shady N, DeCicco-Skinner K.   +9 more
europepmc   +1 more source

Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation. [PDF]

Adv Sci (Weinh)
Lin Z, Yao M, Xu X, Zhang D, Xu L, Rong L, Wang X, Duan Y, Chen C, Gu J, Zhang Y, Liu Q, Ye Q, Cui G, Hao Y, Ma X.   +15 more
europepmc   +1 more source

Signal transduction in c-erbB-2 pathway

, 1992
openaire   +1 more source

Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomics. [PDF]

NPJ Precis Oncol
Hunt AL, Randall J, Ogata JD, Johnston L, Swain W, Melvin S, Sharma M, Calvert V, Maxwell GL, Bateman NW, Petricoin EF, Conrads TP, Cannon TL.   +12 more
europepmc   +1 more source

PanERBB CAR T-cells: Shifting gears toward a cure for fanconi anemia head/neck cancers. [PDF]

Mol Ther Oncol
Wiek C, Hüsken S, Scheckenbach K, Eikelberg I, Niktoreh N, Hanenberg H.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

C-erbB-2 Immunostaining in Laryngeal Cancer

Acta Oto-Laryngologica, 1999
Tumour progression is strongly associated with a series of specific genetic changes in protooncogenes and tumour suppressor genes. One of the potential factors involved in tumorogenesis of squamous cell carcinomas is protooncogene c-erbB-2 (also known as neu or HER2). The authors analysed the expression of c-erbB-2 oncoprotein in 154 cases of laryngeal
T, Krecicki, M, Jeleń, M, Zalesska-Krecicka   +2 more
openaire   +3 more sources

Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2

Molecular Immunology, 1991
BCA200 has been described as a 200,000 Mr monomeric cell surface glycoprotein associated with human breast cancer. Since the physical properties and cellular distribution of BCA200 resemble those of c-erbB-2, antibodies to BCA200 were tested for the ability to bind a recombinant protein containing the c-erbB-2 extracellular domain (erbB-2 ECD).
D B, Ring, R, Clark, A, Saxena
openaire   +2 more sources

C‐ErbB‐2 Oncoprotein Immunostaining In Serous Effusions

Cytopathology, 1993
The product of c‐erbB‐2 gene is detected in a proportion of carcinomas from various sites and is generally associated with a high degree of malignancy. A series of 58 effusions containing malignant cells and 16 cytologically negative serous effusions was assessed by immunocyto‐chemical methods for c‐erbB‐2 expression using the monoclonal antibody NCL ...
ASCOLI, Valeria, C. C.A.R.N.O.V.A.L.E. SCALZO, F. NARDI   +2 more
openaire   +3 more sources

c-erbB-2 as a target for immunotherapy

Expert Opinion on Investigational Drugs, 1998
The c-erbB-2 proto-oncogene encodes a 185 kDa transmembrane Type 1 tyrosine kinase receptor whose amplification and/or overexpression has been linked with poor prognosis in a variety of cancers. The oncoprotein has been suggested to play a key role in tumour cell invasion, motility and metastasis, and in responsiveness to therapeutic agents.
openaire   +2 more sources

Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas

Pathobiology, 2008
The c-erbB-2 (neu) gene encodes a transmembrane phosphoglycoprotein (p185erbB-2) which resembles a growth factor receptor-like molecule closely related to the epidermal growth factor receptor. Overexpression of c-erbB-2 induces cell transformation in vitro.
T M, Williams, D B, Weiner, M I, Greene, H C, Maguire   +3 more
openaire   +2 more sources